Chaplains, Decisions, and the Most Alone of Patients
Paul Mclean Paul Mclean

Chaplains, Decisions, and the Most Alone of Patients

In making decisions about medical treatment for patients who are “incapacitated and alone,” as an influential American Bar Association study once described them, there is a tension among medical judgment, ethics and the law that may be necessary but can do harm to a patient’s best interests.

Read More
Love Wins
Shukong Ou Shukong Ou

Love Wins

“Why?” is one of the first questions we humans ask. Developing ethical justifications to support decisions is an essential part of my participation in the CEC: the details of “why” influences life-and-death decisions made by patients, caregivers, family, and health proxies. Facts are cold. I believe that real life decisions ultimately depend on love.

Read More
When Medical Ethics Enters the Campaign</a>
Paul Mclean Paul Mclean

When Medical Ethics Enters the Campaign

Ethical questions in medical care and science will be prevalent throughout the presidential election season. How deeply they are considered will vary greatly. In the past week, two in particular have come to the fore, and how well they were engaged is worth considering.

Asked in Saturday’s Republican debate whether he would consider quarantining Americans returning this summer from the Olympics in Brazil, New Jersey Gov. Chris Christie said, “You bet I would.”

Read More
Even Gene Editors Need an Editor
Paul Mclean Paul Mclean

Even Gene Editors Need an Editor

Perhaps the confusion is best explained by an exchange toward the end of the summit, when organizers were asked if their statement might be translated into clearer language more easily understood by the public. To which Dr. David Baltimore, principle organizer of the summit and former president of CalTech, said: “You mean it isn’t?”

Read More
Getting a Handle on CRISPR/Cas9 (Part 2)</a>
Paul Mclean Paul Mclean

Getting a Handle on CRISPR/Cas9 (Part 2)

Takeaways from Day 2 of the International Summit on Human Gene Editing. The challenge: Not devoting all of them to legal scholar and doctor of irony Barbara Evans.

Read More
Getting a Handle on CRISPR/Cas9 (Part 1)
Paul Mclean Paul Mclean

Getting a Handle on CRISPR/Cas9 (Part 1)

One day into the International Summit on Human Gene Editing in Washington, D.C., I’m struck by how easy it is for a lay person (namely myself) to get lost in the science. That gulf in comprehension complicates the effort to earn public buy-in and trust for use of the new technology.

Read More